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RESEARCH
Closed incision negative pressure wound therapy versus  
standard dressings in obese women undergoing caesarean  
section: multicentre parallel group randomised controlled trial
Brigid M Gillespie,1,2 Joan Webster,3 David Ellwood,2,4 Lukman Thalib,5 Jennifer A Whitty,6,7  




To determine the effectiveness of closed incision 
negative pressure wound therapy (NPWT) compared 
with standard dressings in preventing surgical site 
infection (SSI) in obese women undergoing caesarean 
section.
Design
Multicentre, pragmatic, randomised, controlled, 
parallel group, superiority trial.
setting
Four Australian tertiary hospitals between October 
2015 and November 2019.
ParticiPants
Eligible women had a pre-pregnancy body mass index 
of 30 or greater and gave birth by elective or semi-
urgent caesarean section.
interventiOn
2035 consenting women were randomised before 
the caesarean procedure to closed incision NPWT 
(n=1017) or standard dressing (n=1018). Allocation 
was concealed until skin closure.
Main OutcOMe Measures
The primary outcome was cumulative incidence of 
SSI. Secondary outcomes included depth of SSI 
(superficial, deep, or organ/body space), rates of 
wound complications (dehiscence, haematoma, 
seroma, bleeding, bruising), length of stay in hospital, 
and rates of dressing related adverse events. Women 
and clinicians were not masked, but the outcome 
assessors and statistician were blinded to treatment 
allocation. The pre-specified primary intention to treat 
analysis was based on a conservative assumption of 
no SSI for a minority of women (n=28) with missing 
outcome data. Post hoc sensitivity analyses included 
best case analysis and complete case analysis.
results
In the primary intention to treat analysis, SSI occurred 
in 75 (7.4%) women treated with closed incision 
NPWT and in 99 (9.7%) women with a standard 
dressing (risk ratio 0.76, 95% confidence interval 
0.57 to 1.01; P=0.06). Post hoc sensitivity analyses 
to explore the effect of missing data found the same 
direction of effect (closed incision NPWT reducing 
SSI), with statistical significance. Blistering occurred 
in 40/996 (4.0%) women who received closed 
incision NPWT and in 23/983 (2.3%) who received 
the standard dressing (risk ratio 1.72, 1.04 to 2.85; 
P=0.03).
cOnclusiOn
Prophylactic closed incision NPWT for obese 
women after caesarean section resulted in a 24% 
reduction in the risk of SSI (3% reduction in absolute 
risk) compared with standard dressings. This 
difference was close to statistical significance, but 
it likely underestimates the effectiveness of closed 
incision NPWT in this population. The results of the 
conservative primary analysis, multivariable adjusted 
model, and post hoc sensitivity analysis need to be 
considered alongside the growing body of evidence 
of the benefit of closed incision NPWT and given 
the number of obese women undergoing caesarean 
section globally. The decision to use closed incision 
NPWT must also be weighed against the increases 
in skin blistering and economic considerations and 





The use of caesarean section in birthing women varies 
widely, with Nordic countries reporting low rates and 
other Western countries such as Australia, Canada, the 
UK, and the US reporting higher rates (15-17% v 25-
32%).1 Compared with vaginal birth, caesarean section 
is associated with increased morbidity and mortality.2 
The World Health Organization defines people as obese 
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WhAt Is AlreAdy knoWn on thIs topIc
A 2014 Cochrane systematic review compared closed incision negative pressure 
wound therapy (NPWT) with a standard dressing for surgical site infection (SSI), 
wound complications, and time to healing
Evidence for the effect of closed incision NPWT in preventing SSI and wound 
complications was unclear, and the overall quality of the evidence was low
A more recent meta-analysis including seven studies reported inconclusive 
evidence of the effectiveness closed incision NPWT for obese women giving birth 
by caesarean section
WhAt thIs study Adds
The results of this large trial add to the body of evidence in published systematic 
reviews suggesting that prophylactic closed incision NPWT may be effective in 
reducing SSI rates
The use of prophylactic closed incision NPWT for obese women undergoing 
caesarean section was associated with a small but significant increase in skin 
blistering
The use of closed incision NPWT in obese women undergoing caesarean section 
needs to be considered alongside the risk of blistering and cost effectiveness
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if their body mass index is greater than or equal to 
30.0.1 Obesity in pregnancy is increasingly common; 
in Australia, more than 50% of women are overweight 
or obese on entering pregnancy.1 Postoperative wound 
complications such as surgical site infection (SSI), 
dehiscence (splitting open of a surgically closed 
wound), and formation of haematoma and seroma 
are common complications of surgical procedures,3 
particularly among women with obesity, diabetes, 
or both.4 SSI is an important global concern that can 
contribute to re-intervention and treatment, increased 
length of stay in hospital, delayed wound healing, and, 
in some cases, death.5 6 Maternal obesity increases 
the woman’s risk of developing SSI and other wound 
complications threefold, which delays recovery, 
increases discomfort, and reduces quality of life.4 7
Over the past decade, the use of single use closed 
incision negative pressure wound therapy (NPWT) 
dressings in high risk surgical incisions has been 
increasing, with the aim of reducing the risk of SSI 
and other associated wound complications.8 Closed 
incision NPWT is a sealed non-invasive system that 
applies suction (negative pressure) on the wound site 
that has been closed, for example, by sutures, staples, 
or glue. The surgical incision is covered with semi-
occlusive adhesive dressing connected by tubing to 
a suction pump.9 The suction pump exerts negative 
pressure to the closed incision and removes wound 
fluid with recommended pressures usually between 
–50 mm Hg and –125 mm Hg,10 depending on the 
manufacturer’s instructions.11 The mechanism of 
action is unclear but is purported to include reduced 
bacterial entry into the wound while removing blood 
and exudate and stimulating granulation.
In 2010-11, two simplified NPWT devices became 
commercially available (Prevena (KCI) and PICO (Smith 
& Nephew)). A Cochrane review published before we 
started this trial and its subsequent update found only 
low quality evidence in any population, with most 
studies sponsored by industry.8 12 Meta-analytic results 
of the updated Cochrane review reported inconclusive 
evidence of the effectiveness of closed incision NPWT 
specifically for obese women undergoing caesarean 
section (seven studies).8 At the time we began our 
research, all other trials in this population were 
small, single site, and industry funded. In this study, 
we aimed to compare the effectiveness and safety 
of prophylactic closed incision NPWT and standard 
surgical dressings on the cumulative incidence of SSI 
in obese women undergoing elective and semi-urgent 
caesarean section.
Methods
study design and participants
We conducted a pragmatic, randomised, controlled, 
parallel group, superiority trial in four large public 
hospitals in southeast Queensland, Australia. We made 
no changes to the methods after the start of the trial. We 
identified potentially eligible women at their routine 
36 week antenatal visit. Research nurses at each 
site screened women in antenatal clinics, antenatal 
wards, and birthing suites. Women were eligible if they 
were booked for elective (category 4) or semi-urgent 
(categories 2-3) caesarean section,13 recorded a pre-
pregnancy body mass index of 30 or higher, and were 
able to provide written informed consent. We excluded 
women who needed an urgent caesarean section 
(category 1), had an infection in hospital including 
during labour or immediately before caesarean section, 
had participated in the trial in a previous pregnancy, 
or were unable to speak or understand English with 
no interpreter present. Written informed consent was 
obtained from all participants. The protocol has been 
published.14
randomisation and masking
We used a web based central randomisation service to 
randomly assigned eligible, consenting women (1:1) 
just before the caesarean procedure to receive either a 
closed incision NPWT dressing or the standard hospital 
dressing. To ensure that equal numbers of participants 
were assigned to each group, we used random block 
sizes of four, six, and eight, stratified by hospital. 
Allocation was concealed until after skin closure. 
The nature of the intervention meant that women, 
clinical staff, and research staff were not blinded 
to treatment after allocation. Data were reviewed 
by two independent, blinded outcome assessors to 
determine primary and secondary wound endpoints, 
and discrepancies were adjudicated by a third blinded 
assessor. Principal investigators, including the trial 
statistician, were also blinded to group allocation. 
The clinical trial coordinator trained and supervised 
research nurses and audited the quality of data and 
compliance of randomisation.
Procedures
All women received standard care, according to local 
hospital and national health department guidelines.15 
Before the skin incision, the woman’s abdomen 
was prepared with either alcoholic or aqueous 
chlorhexidine or betadine. All women received a 
lower transverse suprapubic skin incision, and two 
obstetricians, usually a trainee registrar supervised by 
a consultant, carried out the operation. The method 
of skin closure (suture or staples) was based on the 
obstetrician’s preference. The operating obstetrician 
(or delegate) applied the closed incision NPWT and 
standard dressings under sterile conditions in the 
operating room immediately after skin closure. Women 
assigned to the closed incision NPWT group received 
a PICO dressing (Smith & Nephew, Hull, UK), which 
was left intact for approximately five to seven days as 
recommended by the manufacturer. This particular 
NPWT product was used in two earlier pilot studies.16 17 
The PICO product (size 10×30 cm or 10×40 cm) has 
a small discrete pump powered by two AA lithium 
batteries with an absorbent polyurethane foam dressing 
that holds wound exudate away from the skin. A tube 
is inserted into the foam, and a continuous negative 
pressure of 80 mm Hg is applied after application of 
the dressing. The PICO dressing was reinforced around 
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each of the four edges with four pieces of adhesive tape 
included in the dressing kit, as per the manufacturer’s 
instructions. All clinical staff providing care received 
ongoing training and support in the correct application 
and use of the PICO dressings, as well as monitoring 
dressing changes and completing documentation daily 
for assessment of protocol fidelity.
The control group comprised women allocated to 
the standard hospital dressing. The choice of standard 
dressings was based on the treating obstetrician’s 
usual choice of dressing (for example, hydrocolloid or 
transparent), applied according to the manufacturer’s 
recommendations after skin closure in the operating 
room. Across all hospital sites, the standard dressing 
was left intact for five to seven days.
We collected clinical data from several sources, 
including electronic records, direct observation, and 
self-reporting by women during hospital admission 
and after discharge. Demographic data (pre-pregnancy 
body mass index, parity/gravidity, comorbidities, 
measurement of health status (Health Related Quality 
of Life Short Form Survey SF-12 v-2) were obtained 
on enrolment; surgical data (American Society of 
Anaesthesiologists category, type of anaesthetic, 
antibiotic administration, hair removal method, 
surgical approach, wound closure layers, suture 
materials, length of operation) were obtained on 
the day of the caesarean section. Research nurses 
visited women on postoperative day 2 and collected 
vital signs, SSI related data using a structured tool 
based on the Centres of Healthcare Related Infection 
Surveillance and Prevention guidelines identifying 
signs and symptoms of SSI (that is, redness, swelling, 
pain/tenderness, watery or purulent discharge),18 pain 
associated with the dressing, and women’s satisfaction 
with the NPWT dressing. After discharge from hospital, 
research nurses conducted telephone interviews with 
all women weekly (from the day of their surgery) until 
28 days after discharge. They asked women a series of 
questions about SSI symptoms, SF-12 v2, and related 
resource use including health professional visits. On day 
30, research nurses audited all participants’ hospital 
electronic health records to check for documented 
evidence of SSI and wound complications (chart data 
documented wound complications, reoperations and 
hospital readmission due to wound complications, use 
of antibiotics for wound complications, type of SSI, 
signs and symptoms of SSI).
Outcome assessors were blinded to group 
allocation, the intervention and its comparator, and 
study hypotheses. These assessors were experienced 
registered nurses and performed outcome assessment 
of primary (SSI) and secondary wound related outcomes 
(SSI type, wound complications) for all women enrolled 
in the study. Each outcome assessor independently 
ascertained wound outcomes, and regular inter-rater 
consistency checks were undertaken throughout the 
trial. Where discrepancies in assessment of signs and 
symptoms existed, a third outcome assessor (nurse 
practitioner in wound care) adjudicated decisions. 
We defined loss to follow-up as lacking both 30 day 
medical record data and follow-up phone interview 
data over the four weekly time points on the primary 
outcome (SSI). Thus, a woman might be missing up to 
three interviews but would not be considered lost to 
follow-up unless her 30 day chart was also missing. 
Each week, nurses attempted to contact women or 
their contact person up to three times. Therefore, for 
all women who were not lost to follow-up and did not 
withdraw their participation after randomisation, we 
had data on primary outcome, SSI type (where SSI 
occurred), and wound complications.
All data were entered directly into secure portable 
tablets using a purpose built research data capture 
(REDCap) database and form based interface. Research 
nurses had access to the data at their hospital site only, 
and clinical staff did not have access to research data. 
The clinical trial coordinator audited the quality and 
completeness of data and adherence to the protocol, as 
well as visiting sites for training and monitoring.
Outcomes
The primary outcome was the cumulative incidence 
of SSI at 30 days after surgery, as defined by Centers 
for Disease Control and Prevention (CDC) guidelines. 
Secondary clinical outcomes included type of SSI 
(superficial, deep, or organ/body space),18 any type 
of wound complication (dehiscence, haematoma, 
seroma, bleeding), type/number of individual wound 
complications, length of stay in hospital, and number 
of wound related hospital readmissions in the 30 
days after surgery. Definitions and measures used 
for primary and secondary outcomes are included in 
supplementary table A.
Other secondary outcomes, including dressing 
related adverse events, such as rash, itchiness, and 
blistering, were assessed by research nurses. Serious 
adverse events (maternal death, admission to intensive 
care unit, life threatening condition) were monitored 
and reported to the human research ethics committee 
at each site. An independent Data Safety Monitoring 
Committee was established to assess the safety of 
the intervention. This committee, comprising an 
obstetrician, a statistician, and an infection control 
nurse specialist, oversaw the trial and reviewed interim 
analyses, undertaken twice during the life of the trial. 
The trial would not be stopped unless the committee 
deemed that significant safety problems were present 
during safety monitoring of the trial intervention.
statistical analysis
We calculated the sample size on the basis of the 
proportion of women who developed an SSI within 
30 days of caesarean section. On the basis of previous 
work in this area,19 we conservatively estimated that 
15% of women in the control group were likely to 
develop an SSI. Following discussions with infectious 
disease experts and obstetricians, we determined that 
an absolute reduction in the rate of SSI of 5 percentage 
points would be clinically important. The sample 
size needed to detect a reduction in the cumulative 
incidence of SSI at 30 days from 15% to 10% was 
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950 per group (90% power and 5% significance level; 
Power Analysis & Sample Size system (PASS, V.12), 
NCSS). We inflated the sample size by 10% to allow for 
loss to follow-up (n=1045 per group; total sample size 
2090 women).
We summarised baseline characteristics comprising 
binary data by using counts and proportions and 
continuous data as mean and standard deviation or 
median and interquartile range, depending on the 
distribution. We used Cohen’s κ to calculate inter-rater 
consistency between outcome assessors.
The pre-specified primary outcome analysis was 
by intention to treat. For women lost to follow-up and 
withdrawn from the study post-randomisation who 
were missing the primary outcome, we conservatively 
(favoured standard treatment, as it had higher levels 
of missing data) assumed that they did not develop 
an SSI (worst case analysis). As per the protocol, we 
explored differences in prognostic variables between 
groups. The prognostic factors assessed were identified 
in the literature20 21 and based on expert opinion 
(body mass index, age, diabetes, smoking, rupture of 
membranes, parity, caesarean section elective/semi-
urgent, and length of procedure). We found differences 
between groups relative to body mass index and group 
allocation. Thus, following the protocol, we analysed 
the primary outcome by using a logistic regression 
model, adjusting for these.
We used a planned per protocol analysis of treatment 
for device related and serious adverse events. We 
compared binary outcomes (that is, SSI, wound 
complications, adverse/serious adverse events) by 
using a χ2 test or Fisher’s exact test and risk ratios with 
95% confidence intervals. We reported continuous 
variables with non-normal distribution (that is, length 
of surgery, length of stay in hospital) by using medians 
and interquartile ranges and compared them by using 
a Mann-Whitney U test. For all inferential tests, we 
considered a P value below 0.05 to be statistically 
significant.
Post hoc analyses
To check for the robustness of conclusions to the effect 
of assumptions around missing primary outcome data, 
we repeated the intention to treat analysis as described 
above assuming that all women missing the primary 
outcome did have an SSI (favouring closed incision 
NPWT; that is, best case analysis) and excluding 
women missing the primary outcome (complete case 
analysis). Additionally, we did a per protocol analysis 
excluding women lost to follow-up, women withdrawn 
after randomisation, and women treated against their 
randomised allocation (for example, treated with 
closed incision NPWT when in the standard dressing 
arm).
Secondary outcomes (type of SSI, wound compli-
cations, length of stay in hospital, readmissions, pain, 
reoperations) were analysed by complete case analysis 
(excluding women without primary outcome) and by 
per protocol analysis (as with the primary outcome: 
excluding women lost to follow-up, women withdrawn 
post-randomisation, and women treated against their 
randomised allocation).
Patient and public involvement
Patients were not involved in defining the research 
question or outcome measures or in the interpretation 
or writing up of results of this study. This study was 
conceived in 2013, when the patients as co-researchers 
movement had not widely been adopted in Australia.
results
Between 26 October 2015 and 1 November 2019, 
8558 of the 12 077 women screened were excluded, 
leaving 3519 women who were eligible. However, 
338 (9.6%) could not be recruited as their caesarean 
section occurred after hours, and 1072 women were 
not enrolled for various reasons, including refusals, 
vaginal delivery, or delivery at another facility; 2109 
(60%) women were enrolled. We randomly assigned 
2035 women to receive NPWT (n=1017) or standard 
surgical wound dressings (n=1018) (fig 1). Follow-
up concluded on 1 December 2019. Intention to treat 
analysis of primary and secondary outcomes (SSI, type 
of SSI, wound complications, length of stay in hospital, 
readmissions, pain, reoperations) included the 2035 
women randomly assigned to the intervention and 
control groups.
Baseline demographic and obstetric characteristics 
were similar between groups (table 1). The average age 
of participants was 31 (SD 5.5; range 16-54) years. 
Half of all women (1012; 50%) had a pre-pregnancy 
body mass index of 35 or higher (range 30-72), and 
most (1472; 72%) had an elective caesarean section. 
One third of women (657; 32%) across the sample had 
either gestational diabetes or diabetes mellitus. At the 
time of caesarean section, most women (1729; 85%) 
had intact membranes. Most women (1942; 95%) had 
subcutaneous layer closure in addition to subcuticular 
(skin) closure; staples were rarely used (27; 1%). Inter-
rater reliability between outcome assessors for the 
primary outcome SSI and the secondary outcome type 
of SSI yielded κ=0.764 (95% confidence interval 0.72 
to 0.81), and κ=0.712 (0.66 to 0.76), respectively.
In the primary analysis, our “worst case” intention 
to treat analysis assumed that women whose primary 
outcome was missing did not develop SSI (table 
2). The SSI rate across the entire sample was 8.6% 
(n=174). We observed a 3 percentage point reduction 
in the absolute risk of SSI in women treated with NPWT 
compared with standard dressings; this difference 
was not statistically significant (7.4% v 9.7%; risk 
ratio 0.76, 95% confidence interval 0.57 to 1.01; 
P=0.06) (table 2). In terms of SSI type, only 1 (<1%) 
woman in the NPWT group developed an organ/
space SSI (table 2). The rates of all types of wound 
complications in the intervention and control groups 
were comparable. Wound dehiscence was the most 
common complication in both groups (10.6% v 10.1%; 
risk ratio 1.05, 0.81 to 1.36; P=0.71). More hospital 
readmissions occurred in the intervention group than 
in the control group, although this difference was not 
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statistically significant (2.3% v 1.3%; risk ratio 1.76, 
0.90 to 3.46; P=0.09) (table 2).
No differences between the groups in the 
distribution of prognostic factors were apparent (table 
1). Multivariable logistic regression analysis, including 
all a priori identified prognostic factors, showed that 
body mass index 40-49.9 (P=0.02) was a statisti-
cally significant model covariate (model likelihood 
χ2=26.16, df 11; P<0.05; Nagelkerke R2=2.9). The full 
results are shown in supplementary table B.
We did a planned per protocol analysis for dressing 
related adverse events and serious adverse events (table 
3). Dressing related adverse events reported included 
skin blistering, itchiness, and rash. We observed a 2 
percentage point increase in the absolute risk of skin 
blistering among women in the closed incision NPWT 
group, which was statistically significant (4.0% (40) v 
2.3% (23); risk reduction 1.72, 1.04 to 2.85; P=0.03). 
Overall, 17 serious adverse events occurred, including 
three neonatal deaths. Rates of serious adverse events 
were low and did not differ between intervention 
and control groups (intensive care unit admission, 
life threatening condition: 1.2% v 0.5%; risk ratio 
2.57, 0.92 to 7.17; P=0.06). Most of the admissions 
to intensive care related to the lack of available high 
dependency unit beds. One woman developed a 
pulmonary embolism. All serious adverse events were 
reported to the ethics board, and none was deemed 
related to the intervention.
Post hoc sensitivity analyses
Post hoc sensitivity analyses of the cumulative 
incidence of all types of SSI favoured closed incision 
NPWT therapy compared with our main crude analysis 
(reported above). The “best case” intention to treat 
analysis assumed that women with missing outcome 
data developed SSI (supplementary table C). The 
SSI incidence across the entire sample was 9.9% 
(n=202). We observed a 4 percentage point reduction 
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Fig 1 | trial profile. nPWt=negative pressure wound therapy
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table 1 | baseline demographics and obstetric characteristics of intention to treat population (n=2035)
Demographic and obstetric characteristics
no (%) participants*
risk difference  
(95% ci)




Mean (SD) age†, years 31 (5.5) 31 (5.4) 0 (–0.47 to 0.47)
Pre-pregnancy body mass index‡:      
 30.0-34.9 488 (48.0) 524 (51.5) –3.49 (–9.61 to 2.64)
 35.0-39.9 268 (26.4) 247 (24.3) 2.09 (–2.28 to 6.46)
 40.0-49.9 218 (21.4) 211 (20.7) 0.71 (–3.28 to 4.70)
Smoker 101 (9.9) 117 (11.5) –1.56 (–4.41 to 1.28)
Comorbidities:      
 Gestational diabetes 292 (28.7) 288 (28.3) 0.42 (–4.21 to 5.06)
 Diabetes mellitus 38 (3.7) 39 (3.8) –0.09 (–1.78 to 1.60)
 Hypertension 140 (13.8) 129 (12.7) 1.09 (–2.07 to 4.25)
 Respiratory disease 124 (12.2) 142 (13.9) –1.76 (–4.90 to 1.39)
 Anaemia (Hb<110 g/L) in third trimester 99 (9.7) 83 (8.2) 1.58 (–1.02 to 4.18)
 Diagnosed and treated depression 97 (9.5) 103 (10.1) –0.58 (–3.30 to 2.14)
 Thromboembolic disease 82 (8.1) 83 (8.2) –0.09 (–2.56 to 2.38)
 Hypercholesterolaemia pre-pregnancy† 10 (1.0) 4 (0.4) 0.59 (–0.13 to 1.31)
  Immunocompromise  
(on immunosuppressive therapy)
4 (0.4) 5 (0.5) –0.09 (–0.68 to 0.48)
Parity:      
 0 233 (22.9) 264 (25.9) –3.02 (–7.32 to 1.27)
 1 358 (35.2) 374 (36.7) –1.54 (–6.75 to 3.67)
 2 247 (24.3) 202 (19.8) 4.44 (0.36 to 8.53)
 ≥3 179 (17.6) 178 (17.5) 0.12 (–3.52 to 3.76)
No of previous caesarean sections:      
 None 381 (37.5) 421 (41.4) –3.89 (–9.35 to 1.56)
 1 379 (37.3) 383 (37.6) –0.35 (–5.67 to 4.96)
 2 186 (18.3) 156 (15.3) 2.97 (–0.60 to 6.53)
 3 57 (5.6) 44 (4.3) 1.28 (–0.65 to 3.22)
 ≥4 14 (1.4) 14 (1.4) 0 (–1.02 to 1.02)
Status of membrane†:      
 Intact 874 (85.9) 855 (84.0) 1.95 (–6.06 to 9.96)
 Ruptured (≤12 h) 77 (7.6) 80 (7.9) –0.29 (–2.70 to 2.13)
 Ruptured (>12 h) 65 (6.4) 83 (8.2) –1.76 (–4.11 to 0.58)
Surgery types:      
 Elective caesarean section 740 (72.8) 732 (71.9) 0.86 (–6.53 to 8.25)
 Semi-urgent caesarean section 277 (27.2) 286 (28.1) –0.86 (–5.43 to 3.71)
ASA status:      
 1 65 (6.4) 76 (7.5) –1.07 (–3.36 to 1.21)
 2 664 (65.3) 641 (63.0) 2.32 (–4.64 to 9.28)
 3 283 (27.8) 294 (28.9) –1.05 (–5.68 to 3.57)
 ≥4 5 (0.5) 7 (0.7) –0.20 (0.86 to 0.47)
Median (IQR) length of surgery, min† 63 (51.0-77.0) 60 (49.0-75.0) 1.37 (–0.95 to 3.69)
Hair removal methods†:      
 None 138 (13.6) 120 (11.8) 1.78 (–1.31 to 4.88)
 Shaved 164 (16.1) 159 (15.6) 0.51 (–2.95 to 3.97)
 Waxed 56 (5.5) 54 (5.3) 0.20 (–1.81 to 2.22)
 Depilatory cream 5 (0.5) 2 (0.2) 0.30 (–0.21 to 0.80)
 Clipped 653 (64.2) 682 (67.0) –2.79 (–9.82 to 4.25)
Skin preparation†:      
 Aqueous chlorhexidine 74 (7.3) 71 (7.0) 0.30 (–2.02 to 2.62)
 Aqueous betadine 451 (44.3) 462 (45.4) –1.04 (–6.86 to 4.78)
 Alcoholic chlorhexidine 468 (46.0) 459 (45.1) 0.936 (–4.94 to 6.79)
 Alcoholic betadine 22 (2.2) 25 (2.5) –0.29 (–1.61 to 1.03)
Prophylactic antibiotics:      
 Not given 8 (0.8) 12 (1.2) –0.39 (–1.25 to 0.47)
 Pre-incision 985 (96.9) 975 (95.8) 1.08 (–7.45 to 9.61)
 Post-incision 24 (2.4) 31 (3.0) –0.69 (–2.11 to 0.74)
Wound closure:      
 Subcutaneous (fat) closure 966 (95.0) 976 (95.9) –0.89 (–9.38 to 7.60)
 Subcuticular (skin) suture 998 (98.1) 992 (97.4) 0.69 (–7.91 to 9.28)
 Interrupted suture 7 (0.7) 9 (0.9) 0.20 (–0.97 to 0.57)
 Staples (skin) 10 (1.0) 17 (1.7) 0.69 (–1.69 to 0.31)
 Wound glue 2 (0.2) 0 (0) –0.20 (–0.08 to 0.47)
ASA=American Society of Anesthesiologists; Hb=haemoglobin; IQR=interquartile range; NPWT=negative pressure wound therapy.
*Percentages might not add up because of rounding.
†Missing data for ≤5 women.
‡Weight in kilograms divided by square of height in meters.
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incision NPWT compared with standard dressings; 
this difference was statistically significant (8.3% (84) 
v 11.6% 118); risk ratio 0.71, 0.55 to 0.93; P=0.01). 
Results of the complete case analysis showed that the 
incidence of SSI across the whole sample was 8.7% 
(n=174). We observed a 3 percentage point reduction 
in the absolute risk of SSI in women treated with closed 
incision NPWT compared with standard dressings; 
this difference just reached statistical significance 
(7.4% (75) v 9.9% (99); risk ratio 0.75, 0.56 to 1.00: 
P=0.05) (supplementary table D). The results of the per 
protocol analysis that excluded women who did not 
have SSI outcome data were similar to the results of the 
complete case analysis (supplementary table E).
We also did a per protocol analysis of primary 
and secondary outcomes based on 1979 women 
(supplementary table E). In this analysis, we excluded 
the 56 women; 29 (1.4%) did not receive the 
allocated treatment, 16 (<1%) withdrew consent after 
randomisation (this included one woman who did not 
receive the allocated treatment), and 12 (<1%) women 
were lost to follow-up. The exclusion of 56 (2.7%) 
women (with missing data) in the per protocol analysis 
yielded results consistent with the intention to treat 
analysis for the SSI incidence (7.4% (74) v 10% (98); 
risk reduction 0.75, 0.56 to 1.0; P=0.05).
discussion
On balance, the results of the four analytic scenarios 
suggest that closed incision NPWT may be effective in 
reducing SSI in obese women undergoing caesarean 
section. Our pre-specified primary analysis indicated 
that 9% of women in this trial developed an SSI of 
any type—7% in the closed incision NPWT group 
and 10% in the control group. This difference was 
close to statistical significance. The results of the 
best case, complete case, per protocol sensitivity, and 
multivariable analyses were consistent, favouring 
the closed incision NPWT intervention. The primary 
analysis was based on a conservative assumption that 
women lost to follow-up did not develop an SSI; this 
result showed a significant relative reduction of 29% in 
the cumulative incidence of SSI in the closed incision 
NPWT group. It is therefore possible that our primary 
table 2 | clinical outcomes for intention to treat population with missing data on primary outcome (28 women) assumed to be no surgical site infection 
(ssi), conservatively favouring standard care*. values are numbers (percentages) unless stated otherwise
clinical outcomes all (n=2035)




relative risk  
(95% ci) P value†
All SSI types 174 (8.6) 75 (7.4) 99 (9.7) 0.76 (0.57 to 1.01) 0.06
 Superficial 163/174 (94) 70/75 (93) 93/99 (94) 0.75 (0.56 to 1.02) 0.72
 Deep incision 10/174 (5.7) 4/75 (5) 6/99 (6) 0.67 (0.19 to 2.36) 0.72
 Organ/space 1/174 (0.6) 1/75 (1) 0/99 (0) - 0.50
Complications 247 (12.1) 123 (12.1) 124 (12.2) 0.99 (0.79 to 1.25) 0.95
 Bleeding 30 (1.5) 14 (1.4) 16 (1.6) 0.88 (0.43 to 1.79) 0.72
 Dehiscence 211 (10.4) 108 (10.6) 103 (10.1) 1.05 (0.81 to 1.36) 0.71
 Haematoma 17 (0.8) 11 (1.1) 6 (0.6) 1.84 (0.68 to 4.94) 0.22
 Seroma 53 (2.6) 27 (2.7) 26 (2.6) 1.04 (0.61 to 1.77) 0.89
Median (IQR) HLOS, days (n=2019)‡ 3.0 (2.0-4.0) 3 (2.0-4.0) 3 (2.0-4.0) - 0.32
Readmissions‡ 36 (1.8) 23 (2.3) 13 (1.3) 1.76 (0.90 to 3.46) 0.09
Pain‡§ 32 (1.6) 21 (2.1) 11 (1.1) 1.90 (0.92 to 3.93) 0.07
Reoperations‡¶ 9 (0.4) 4 (0.4) 5 (0.5) 0.80 (0.22 to 2.96) 0.75
HLOS=hospital length of stay; IQR=interquartile range; NPWT=negative pressure wound therapy.
*Worst case analysis based on effect estimate; 28 women missing primary outcome data (12 lost to follow-up; 16 withdrawn) assumed not to have SSI (favouring standard dressing as this arm 
has higher levels of missing data).
†Using χ2 test, Fisher’s exact test, or Mann-Whitney U test.
‡Data not available for randomised patients withdrawn from study.
§Pain associated with surgical wound requiring readmission measured as binary variable (yes/no).
¶5 participants had reoperations for wound complications before hospital discharge.
table 3 | safety and adverse events in per protocol population*. values are numbers (percentages) unless stated 
otherwise
clinical outcomes all (n=1979)




relative risk  
(95% ci) P value†
Dressing related adverse events
Blistering 63 (3.2) 40 (4.0) 23 (2.3) 1.72 (1.04 to 2.85) 0.03
 SSI and blistering 21/174 (12) 12/75 (16) 9/99 (9) 1.77 (0.79 to 3.97) 0.16
Itchiness and/or rash 13 (0.7) 10 (1.0) 3 (0.3) 3.29 (0.91 to 11.91) 0.09
serious adverse events
All 17 (0.9) 12 (1.2) 5 (0.5) 2.57 (0.92 to 7.17) 0.06
Neonatal deaths 3 (0.2) 2 (0.2) 1 (0.1) 1.97 (0.18 to 21.73) 1.00
ICU admissions 13 (0.7) 9 (0.9) 4 (0.4) 2.22 (0.69 to 7.19) 0.17
Life threatening condition 1 (0.1) 1 (0.1) 0 (0) - -
ICU=intensive care unit; NPWT=negative pressure wound therapy; SSI=surgical site infection.
*Per protocol population excludes participants (n=56) who were lost to follow-up (12 (<1%) participants), did not receive treatment to which they were 
originally allocated (28 (1%) participants), or subsequently withdrew from study (16 (<1%) participants). 1 participant withdrawn from study did not 
receive treatment to which she was originally allocated.
†Using χ2 test or Fisher’s exact test.
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analysis results underestimate the effectiveness of 
closed incision NPWT in this population, whereas, 
arguably, the results of the post hoc best case 
sensitivity analysis very likely overestimate its 
effectiveness. However, when the results of all analyses 
are considered together, closed incision NPWT seems 
likely to be effective in reducing SSI.
comparison with other studies
Our results across all analytic scenarios were consistent, 
showing no significant differences in the incidence of 
superficial and deep SSI by trial arm. The results of other 
studies using closed incision NPWT in this population 
have yielded mixed results.22-24 Variations in SSI 
rates as reported in other studies in this population 
are likely related to the different definitions used to 
classify and detect SSI,20 smaller samples,16 25 and use 
of pilot and cohort designs,16 22 26 which carry a high 
risk of bias and uncertainty in the results. The results 
of several smaller trials in this population, some of 
which were non-blinded and industry funded, showed 
significant reductions of up to 50% in superficial SSI 
rates.23 26 27 A recently updated Cochrane review of use 
of closed incision NPWT in primary wounds included 
a subgroup analysis of seven studies involving 1886 
obese women undergoing caesarean section.8 The 
results of that subgroup analysis indicated a 27% 
reduction, albeit non-significant, in superficial SSI 
incidence. The results of our trial, the largest in this 
field, suggest that closed incision NPWT may reduce 
superficial SSI incidence in this patient population. 
Given that approximately 29.7 million births occur 
through caesarean section globally,2 this result is 
clinically important. However, the decision to use 
closed incision NPWT in this population needs to be 
considered alongside any economic benefit.
We found no statistically significant differences in 
organ/space SSI. Notably, this study was not powered 
to detect potential differences. Our results are similar 
to previous research in this population.23 26 28 We 
also found no significant group differences in wound 
complications in relation to bleeding, dehiscence, 
haematoma, or seroma.
implications of findings
The finding of a 72% relative increase in blistering 
associated with closed incision NPWT may have 
implications for healthcare decision making. The 
recently updated Cochrane review highlighted very 
low certainty evidence around blistering when com-
paring closed incision NPWT and standard dressings.8 
Whether blistering (under the adhesive dressing and 
tape) occurred because of the dressing itself or the 
adhesive tape that was applied (per manufacturer’s 
instructions) around the dressing to reinforce the 
dressing and help to maintain suction is not clear. 
Results of several previous trials in this population 
reported adverse skin reactions including blistering, 
erythema, and bruising.16 22 28 The occurrence of 
a minor treatable adverse event such as blistering 
that we found in this trial needs to be balanced with 
probable reductions in the incidence SSI. Thus, 
informing women about the potential risks of closed 
incision NPWT, and providing targeted training to 
clinicians in its application, may reduce the potential 
for blistering. Importantly, patients should be partners 
in the decision to use closed incision NPWT as an 
alternative wound management therapy.
The generalisability of our results needs to be 
considered relative to the inclusion criteria applied and 
the low rates of SSI in our study. We excluded women 
undergoing emergency caesarean section because 
they are a different population and their risk factors 
for SSI are not similar to those women undergoing 
elective and semi-urgent caesarean section.21 Also, 
emergency caesarean section as a surgical procedure 
is much less “standardised” than other more “routine” 
caesarean procedures. Given the greater heterogeneity 
of women undergoing emergency caesarean section 
and of emergency caesarean section procedures, and 
wanting to increase internal validity to more precisely 
detect the potential impact of closed incision NPWT, 
we had to control for potential confounding variables 
as much as possible. Therefore, excluding these 
women meant that the caesarean procedure was more 
consistent in its technique and associated processes 
such as skin preparation and antibiotic use. In terms 
of SSI event rates, the baseline infection rate we found 
was much lower than we had assumed in our sample 
size calculation. Our trial was underpowered given the 
low event rate and thus may not be generalisable to 
other clinical settings. The women in this trial probably 
received a high standard of clinical care, based on 
clinical practice guidelines. However, the “true” rate of 
SSI is often underestimated using routinely collected 
surveillance data.29 With the body of evidence for the 
effectiveness of closed incision NPWT growing, our 
findings may be useful for physicians’ and women’s 
decision making regarding dressing type irrespective 
of the centre’s SSI rates.
strengths and limitations of study
Strengths of this study include its sample size, 
the rigorous randomisation, and prospective data 
collection, including weekly follow-up by dedicated 
research staff. The results of a per protocol analysis 
were consistent with the intention to treat analysis, 
indicating minimal effect of missing data and loss to 
follow-up and the robustness of our results. Across both 
intervention and control groups, the time that dressings 
were left in situ was consistent, with both being intact 
for five days. Furthermore, SSI and wound complication 
outcomes were based on the definitions in the CDC’s 
guideline.18 The pragmatic nature of this trial and the 
characteristics of the dressings precluded blinding of 
participants, clinical staff, or data collec tors. However, 
outcome assessors were blinded to group allocation and 
the intervention/comparator. The process of outcome 
ascertainment was rigorous: two blinded outcome 
assessors independently ascertained SSI and wound 
complication data, and a third outcome assessor 
adjudicated any discrepancies. Additionally, agreement 
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among outcome assessors was moderate. A Data Safety 
Monitoring Board provided oversight in terms of safety 
checks. This trial is also one of the few in this area that 
was not funded by industry, thus reducing potential 
biases relative to its conduct and reporting.
However, we note several limitations. Firstly, women 
undergoing urgent (category 1) caesarean section were 
excluded, despite this population having an even higher 
risk of developing a SSI.21 We excluded these women 
because of ethical concerns related to trying to obtain 
valid consent. In most instances, these women would not 
have enough time to consider participation in this trial. 
Secondly, 60% of eligible women were enrolled and, of 
these, 73% had an elective caesarean section, affecting 
generalisability. Generalisability was maximised by 
recruiting women from four large public hospitals, who 
underwent both elective and semi-urgent caesarean 
section. The proportions of women undergoing elective 
versus semi-urgent caesarean section in Queensland 
public hospitals typically reflects the proportions 
recruited in this trial. Thirdly, over the four week data 
collection period, we were able to collect 30 day follow-up 
outcome data for all women except for the 16 women who 
withdrew their consent after randomisation. Fourthly, the 
potential exists for false positive or false negative outcome 
assessments of SSI and wound complications; however, 
blinding and use of two outcome assessors adjudicated 
by a third minimised this risk.
Fifthly, we followed up the women with telephone 
interviews. The decision to use telephone interviews 
was pragmatic; to bring women in weekly to assess 
SSI would have created an increased burden on 
participants and likely resulted in huge loss to follow-
up. We used this approach in preference to having 
missing data. Also, we know that data from routine 
surveillance are inferior in quality to those from 
dedicated follow-up. The survey tool we used was a 
previously validated patient reported tool to assess 
for SSI.30 It had a series of questions about signs and 
symptoms of SSI such as redness, pain/tenderness 
at the incision, and discharge, as well as questions 
related to involvement of health professionals in the 
management of the wound and antibiotics prescribed 
for the wound. To ensure the quality and consistency 
of the data, research nurses used an interview script 
based on SSI symptoms and related resource use. 
Additionally, to minimise loss to follow-up, the 
research nurses contacted women on three separate 
occasions for each week if the women did not answer. 
Other research has shown that self-report of wound 
related complications is accurate when validated tools 
are used.17 30 We cannot rule out the possibility that 
trial participants may have incorrectly reported their 
wound characteristics, but we have no reason to think 
that this was likely to occur.
Sixthly, we did not do time analysis because 
reporting time to SSI using weekly data provides 
limited information. Seventhly, despite the large 
sample size, the cumulative incidence of SSI was lower 
than expected; thus, given the wider 95% confidence 
intervals (less precision) for the primary outcome, 
a false negative result (type II error) is still possible. 
Furthermore, underestimation of the incidence of SSI 
is possible, given the way that missing data have been 
treated in the analysis of primary analysis. Finally, 
we did not have access to general practice data or 
information as to whether women went back to different 
hospitals or on any use of antibiotics for wound 
infection. Therefore, some wound complications and 
infections may have been missed, leading to an under-
estimation of SSI incidence. Nevertheless, the women 
in this study were able to accurately self-report any 
wound related complications and treatments (for 
example, antibiotics).
conclusions
On the basis of our primary intention to treat analysis, 
assigning no SSI to missing data, prophylactic closed 
incision NPWT for obese women after caesarean 
section resulted in a 24% reduction in the relative 
risk of SSI compared with standard dressings 
(3% reduction in absolute risk). This difference, 
although close to statistical significance, possibly 
underestimates the effectiveness of closed incision 
NPWT in this population. On balance, the results 
of the conservative primary, multivariable adjusted 
model, and post hoc sensitivity analyses should be 
considered alongside the growing body of evidence 
of the benefits of closed incision NPWT and given the 
number of obese women undergoing caesarean section 
globally. However, the decision to use closed incision 
NPWT needs to be weighed against the increase in skin 
blistering and economic considerations and based on 
shared decision making.
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